We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byOlivia Jacoway
Modified about 1 year ago
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD, FACC, Christopher P. Cannon MD FACC, Sabina A. Murphy MPH, Jie Qin MS, Kausik K. Ray MD, Eugene Braunwald MD, MACC for the PROVE IT-TIMI 22 Investigators Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Background and Objectives The PROVE IT-TIMI 22 trial demonstrated that LDL-C < 70 mg/dL was associated with greater CHD event reduction than LDL-C <100 mg/dL after ACS. n We evaluated the impact of TG in the PROVE IT-TIMI 22 trial, reasoning that if high LDL-C and TG increases CHD risk more than isolated high LDL-C, then the combination of low on- treatment LDL-C and TG would be associated with reduced CHD risk compared to low LDL-C (< 70 mg/dL) alone. Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply
Methods n Study Population: 4,162 patients in The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial n Blood Sampling: Plasma samples for lipids, lipoproteins, HS-CRP at baseline, 30 d, and 4, 8, 16, 24 months Composite Endpoint: Death, myocardial infarction (MI) or recurrent ACS between 30 d and 2 yr follow-up Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Methods (2) Statistical Analysis Kaplan-Meier event rates after censoring events within 30 days of initial ACS event. Cox proportional hazards model: Age, gender, DM, HTN, obesity (BMI > 30 kg/m 2 ), cigarette smoking (active), low HDL-C to estimate effect of on-treatment LDL-C (70 mg/dL) and TG (150 mg/dL) within 30 days or 4 months of initial ACS event. CRP (2 mg/L) included to assess triple goal attainment Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Days After Month 1 Visit TG < 150 TG ≥ 150 HR: 0.73 (0.62, 0.87) P < Days After Month 1 Visit LDL < 70 LDL ≥ 70 HR: 0.81 (0.68, 0.96) P = Kaplan-Meier Estimates Based on LDL-C < 70 mg/dL or TG < 150 mg/dL Between 30 days and 2 yr Follow-Up Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results TG < 150TG ≥ 150 LDL-C < 70 LDL-C ≥ 70 Rate of Death, MI or Recurrent ACS after 30 days Adjusted for age, sex, smoking, DM, HTN, obesity, HDL, PVD, prior ACS, prior statin use and treatment effect Hazard of Death, MI & Recurrent ACS with on-treatment LDL-C (70 mg/dL) & TG (150 mg/dL) Ref 17.9% 15.0% 16.5% 11.7% P = P = P = HR: 0.84 ( ) HR: 0.85 ( ) HR: 0.72 ( ) Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Proportion of Pravastatin (40 mg) and Atorvastatin (80 mg) Treated Patients Attaining LDL-C < 70, CRP < 2 & TG < 150 at 30 days Proportion of on-treatment 35%* * P < between the treatment groups 6.6% Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Hazard of death, MI and recurrent ACS with number of goals achieved based on LDL-C < 70, CRP < 2 & TG < 150 mg/dL at 30 d 35%* 6.6% Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply. Adjusted for age, sex, smoking, DM, HTN, obesity, HDL, PVD, prior ACS, prior statin use and treatment effect
On-treatment TG < 150 mg/dL was associated with a lower risk of recurrent CHD events independently of the level of LDL-C. Therefore, these data lend support to the concept that achieving both a low LDL-C and low TG may be important therapeutic parameters following ACS Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply. Conclusions
© 2010 CV Health: Three Ways to ‘kNOw’ Kathleen O’Neil-Smith, MD Malden, MA.
AHA/ASA Guideline Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals.
A New Look at CHD Risk Factors Total Cholesterol LDL-Cholesterol HDL-Cholesterol Lipoprotein(a) Homocysteine Particle size/density Lp subclasses.
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Womens Hospital that relate.
TCT 2011 | San Francisco, CA | November 10, 2011 Two-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe.
The Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA) Blood Pressure Variability and Cardiovascular Outcomes PS Sever,
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
The concept of Diabetes & CV risk: A lifetime risk challenge John Deanfield, MD University College London London, United Kingdom Cardio Diabetes Master.
Charles V. Pollack Jr, MA, MD, FACEP, FAAEM Program Chairman Chairman, Department of Emergency Medicine Pennsylvania Hospital Professor of Emergency Medicine.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer,
Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study.
Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.
22d Medical Group 1 Lp-PLA 2 Testing PLAC Capt J. Brian Clark SSgt James Baluyot McCONNELL AFB, KS (AMC) UNCLASSIFIED SAFMLS, MARCH 2010.
Presenter Disclosure Information Jochen Senges The following relationships exist related to this presentation: Speaker CompensationTrommsdorff ArzneimittelModest.
Current issues in co-morbidities and complications Cristina Mussini.
Reducing Cardiovascular Risk in Patients With Diabetes Robert J Bulgarelli DO FACC CMA Director Integrative Cardiology - MLHS CMO – the Habit Change Company.
Young-Hak Kim, MD, PhD on behalf of the PREVENT investigators Preventive Strategies of REnal Insufficiency in Patients with Diabetes Undergoing InterVENTion.
Type II Diabetes Gil C. Grimes, MD Assistant Professor Community and Family Medicine Scott and White Memorial Hospital September 2007.
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
Simulations The basics for simulations. Simulation is a way to model random events, such that simulated outcomes closely match real-world outcomes. By.
Quality and Use in Managed Care Sarah Hudson Scholle Academy Health Annual Research Meeting Seattle June 26, 2006.
Società Italiana per lo Studio dell Aterosclerosi Sez. Regionale Lombarda DEATH DUE TO CHD IN THE USA IN 1986 BUSH, ANN NY ACAD SCI,1990.
Predictors of Acute, Subacute and Late Stent Thrombosis After Acute MI Primary Angioplasty in the Horizons AMI Trial George D. Dangas, Alexandra J. Lansky,
Cost and Price in Massachusetts Center-Based Care and Results of the 2009 Price Study.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
The Role of ACEIs in Unstable Angina Sukhjinder Sidhu Interior Health Pharmacy Resident Cardiology Rotation February 21, 2014.
Diabetic Nephropathy in T2DM: Blood Pressure and Cholesterol Targets Nemanja Stojanović Consultant Endocrinologist Queens Hospital, Romford.
LONGVIEW: COGNITIVE CAPITAL OVER THE LAST 50 YEARS SEMINAR 5 ADULT LIFE CHANCES: HEALTH Based on work led by David Batty, Catherine Gale, Stephani Hatch,
Diabetic Medication Update Gil C. Grimes, MD April 2007.
© 2016 SlidePlayer.com Inc. All rights reserved.